Legal14 Jul 2025, 04:27 pm
Sun Pharma Announces Settlement with Incyte Corporation in LEQSELVI™ Litigation
AI Summary
Sun Pharmaceutical Industries Limited and Incyte Corporation have entered into a settlement and license agreement regarding litigation related to LEQSELVI™ (deuruxolitinib). The parties will seek dismissal of the pending LEQSELVI litigation in the United States District Court for the District of New Jersey. Incyte has granted to Sun a limited, non-exclusive license to U.S. Patent Nos. 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, in the U.S. Sun will pay to Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license.
Key Highlights
- Sun Pharma and Incyte Corporation have settled litigation related to LEQSELVI™ (deuruxolitinib)
- The parties will seek dismissal of the pending LEQSELVI litigation in the United States District Court for the District of New Jersey
- Incyte has granted to Sun a limited, non-exclusive license to U.S. Patent Nos. 9,662,335 and certain other related patents
- Sun will pay to Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents
- The settlement and license agreement terms are confidential